Navigation Links
PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced today that it has recently completed a collaboration with LigoCyte Pharmaceuticals, Inc. Under the collaborative agreement, PacificGMP produced master cell and baculovirus banks and will provide storage services under cGMP (current good manufacturing practices) standards for LigoCyte's norovirus vaccine program. Furthermore, PacificGMP conducted the services under an accelerated timeline.

"We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate," said Leigh N. Pierce, President of PacificGMP. "The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule."

"Through their diligent efforts, PacificGMP demonstrated their GMP proficiency and allowed us to maintain our program timelines," said Bryan Steadman, Senior Director of CMC Operations for LigoCyte. "We appreciate PacificGMP's assistance in the development of our vaccine for norovirus infection, an illness that afflicts an estimated 23 million individuals in the U.S. annually, frequently resulting in serious medical consequences."

About PacificGMP

PacificGMP is a contract manufacturer and industry leader in single-use technology for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP partners with drug developers by providing a range of cGMP and non-GMP services from cell line optimization, early process design, development, purification and scale-up, to preclinical and clinical manufacturing, aseptic filling, testing, analytical services and regulatory support. More information can be found by visiting the Company's web site at www.PacificGMP.com.

About LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals is a private biopharmaceutical company focused on the development of innovative vaccine products based on the company's proprietary virus-like particle platform technology. LigoCyte's lead candidate recently completed a Phase I clinical trial. The vaccine is being developed for the prevention of norovirus gastroenteritis, an illness that causes an estimated 64,000 hospitalizations and 900,000 clinical visits among children annually in the U.S, according to the CDC. LigoCyte also has a novel influenza vaccine in preclinical development that has, notably, demonstrated protection in ferrets across multiple influenza subtypes with a single VLP antigen. Incorporated in 1998, LigoCyte has 45 employees and is located in Bozeman, Montana. Please visit www.ligocyte.com for more information.

    Contact:

    PacificGMP
    Gary Pierce
    Chief Business Officer
    858-550-4094

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Leigh Pierce

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271


'/>"/>
SOURCE PacificGMP
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
2. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
3. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
4. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
5. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
6. Tigris Pharmaceuticals Files IND Application for GGTI-2418
7. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
8. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
9. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):